Shares of Agenus Inc. (NASDAQ:AGEN) traded down 6.3% during trading on Tuesday . The stock traded as low as $4.44 and last traded at $4.50, with a volume of 749,535 shares changing hands. The stock had previously closed at $4.80.

Several analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating on shares of Agenus in a research report on Saturday, April 30th. Maxim Group reissued a “buy” rating on shares of Agenus in a research note on Wednesday, April 27th. Finally, Zacks Investment Research raised shares of Agenus from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $10.47.

The firm has a 50-day moving average price of $4.28 and a 200-day moving average price of $3.79. The company’s market cap is $393.58 million.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Thursday, April 28th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.14. On average, analysts expect that Agenus Inc. will post ($1.36) EPS for the current year.

In other Agenus news, CEO Garo H. Armen acquired 100,000 shares of the stock in a transaction dated Monday, May 9th. The shares were bought at an average price of $3.18 per share, with a total value of $318,000.00. Following the purchase, the chief executive officer now directly owns 1,346,026 shares of the company’s stock, valued at approximately $4,280,362.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.